

Equality and Health Impact Assessment

Medicines identified as low value for prescribing in NHS Wales

AWTTC will fill in an Equality and Health Impact Assessment in parallel with each development stage of our projects. This will help us to follow the five ways of working for public bodies, and work to achieving the wellbeing goals, outlined in the Well-Being of Future Generations (Wales) Act 2015.

Date: 27/07/2026

1.	AWTTC contact details	Tel: 02921 826900 Email: awttc@wales.nhs.uk
2.	State the objectives of the project.	The purpose of this document is to provide an update to the previously published Low Value for Prescribing guidance supporting the effective use of resources within NHS Wales. This document provides advice to prescribers and health boards in Wales, with the aim of reducing the use of medicines that should not be routinely prescribed. Health board access to the advice contained within this document will enable a more equitable process for making decisions about organisational policies for prescribing.
3.	Evidence and background information considered. For example: • population data • staff and service users' data, as applicable • needs assessment • engagement and involvement findings	In developing this updated document, the previously included medicines have been reviewed for their continued suitability. A Task and Finish group was convened to support the review which comprised medicines management representatives from all health boards. The group deliberated whether medicines should be removed from the active recommendations. The group also reviewed which Value-based Prescribing domain each medicine should be considered within and gave input into which had the greatest need for an extensive updated evidence review of the available literature.

	• research • good practice guidelines • participant knowledge • list of stakeholders and how stakeholders have engaged in the development stages • comments from those involved in the designing and development stages Population pyramids are available from Public Health Wales Observatory.	Where medicines have been determined suitable for 'retirement' they have been removed from the active recommendations list. Data will continue to be available for 'retired' medicines to enable monitoring for any increases in usage. The recommendations within the document have all received an evidence review (except for blood glucose monitoring strips) and update to their spend figures. These medicines have been categorised within specific domains according to the Value-based Prescribing programme.
4.	Who will this project affect?	Prescribers, dispensers and patients currently being prescribed named medicines from within document may be affected.

5. EQIA - How will the project impact on people?

Questions in this section relate to the impact on people based on the 'protected characteristics' of the Equality Act 2010, and other factors.

How will the project impact on, or affect:	Potential positive and/or negative impacts	Recommendations for improvement/ mitigation (What could be put in place to decrease any potential negative impacts and increase potential positive impacts?)	Actions taken (and who by). (Refer to where the mitigation is included in the document, as appropriate. State what action will be taken?)
5.1 Age For most purposes, the main categories are people aged: • under 18 years; • between 18 and 65 years; • over 65 years.	We do not expect a potential negative, or unequal, impact on people based on their age. [Note: For prescription medicines we expect the prescriber to have prescribed or advised their use within the terms of their UK marketing authorisations. Healthcare professionals should take note of the contraindications, warnings, safety recommendations and any monitoring needs for the medicine. These are explained in the Summary of Product	N/A at this stage	N/A at this stage

How will the project impact on, or affect:	Potential positive and/or negative impacts	Recommendations for improvement/ mitigation <i>(What could be put in place to decrease any potential negative impacts and increase potential positive impacts?)</i>	Actions taken (and who by). <i>(Refer to where the mitigation is included in the document, as appropriate. State what action will be taken?)</i>
	Characteristics (SmPC) for the medicine or the British National Formulary. Healthcare professionals should follow relevant professional guidance and take full responsibility for the decision when prescribing or advising the use of off-label or unlicensed medicines. This includes considering the contraindications, warnings, monitoring requirements and other safety recommendations for the medicine (MHRA guidance on off-label or unlicensed use of medicines)]		
5.2 Persons with a disability as defined in the Equality Act 2010	We do not expect a potential negative, or unequal, impact on people with a disability.	All related documents published on the AWTTC website will meet accessibility	N/A at this stage

How will the project impact on, or affect:	Potential positive and/or negative impacts	Recommendations for improvement/ mitigation (What could be put in place to decrease any potential negative impacts and increase potential positive impacts?)	Actions taken (and who by). (Refer to where the mitigation is included in the document, as appropriate. State what action will be taken?)
Those with physical impairments, learning disability, sensory loss or impairment, mental health conditions, long-term medical conditions such as diabetes.		requirements. Any patient-facing materials will also be produced in easy read formats in Welsh and English.	
5.3 People of different genders: Consider men, women, people undergoing gender reassignment. N.B. Gender-reassignment is anyone who proposes to, starts, is going through or who has completed a process to change his or her gender with or without going through any medical procedures. Sometimes referred to as Trans or Transgender.	We do not expect a potential negative, or unequal, impact on people based on their gender, or on people undergoing gender reassignment.	N/A	N/A
5.4 People who are married or who have a civil partner.	We do not expect a potential negative, or unequal, impact on people based on their marital status or being in a civil partnership.	N/A	N/A

How will the project impact on, or affect:	Potential positive and/or negative impacts	Recommendations for improvement/ mitigation (What could be put in place to decrease any potential negative impacts and increase potential positive impacts?)	Actions taken (and who by). (Refer to where the mitigation is included in the document, as appropriate. State what action will be taken?)
5.5 Women who are expecting a baby, who are on a break from work after having a baby, or who are breastfeeding. They are protected for 26 weeks after having a baby whether or not they are on maternity leave.	We do not expect a potential negative, or unequal, impact on women who are expecting a baby, are breastfeeding, or are on a break from work after having a baby.	Prescribers should take account of the Summary of Product Characteristics (SmPC) when prescribing any medicines for women who are pregnant, or who are breastfeeding.	The SmPC criteria specify which people are excluded from treatment due to the associated risks of treatment. This will be identified for consideration of any change to the advice at the next review if there is a change to the current advice for pregnant and breastfeeding women.
5.6 People of a different race, nationality, colour, culture or ethnic origin including non-English speakers, gypsies and travellers, migrant workers. The Runnymede Trust	We do not expect a potential negative, or unequal, impact on people of a different race, nationality, colour, culture or ethnic origin. People of different race and ethnicities can have varying responses to medicines.	N/A People of different race and ethnicities can have varying responses to medicines.	N/A

How will the project impact on, or affect:	Potential positive and/or negative impacts	Recommendations for improvement/ mitigation (What could be put in place to decrease any potential negative impacts and increase potential positive impacts?)	Actions taken (and who by). (Refer to where the mitigation is included in the document, as appropriate. State what action will be taken?)
5.7 People with a religion or belief or with no religion or belief. The term 'religion' includes a religious or philosophical belief. Implications of religious beliefs on selection of medicines (BMJ) In practice: guidance on religion, personal values and beliefs (General Pharmaceutical Council)	We do not expect a potential negative, or unequal, impact on people who have a religion or belief, or people with no religion or belief. Some medicines are made from certain animal products and people might not want to take them because of religion or belief.	N/A	N/A
5.8 People who are attracted to other people of: - the opposite sex (heterosexual); - the same sex (lesbian or gay); - both sexes (bisexual). Stonewall	We do not expect a potential negative, or unequal, impact on people based on who they are attracted to.	N/A	N/A
5.9 People who communicate using the Welsh language in terms of correspondence,	We do not expect a potential negative, or unequal, impact on	Any patient-facing materials will be produced in Welsh and English, in line with the Welsh	N/A at this stage

How will the project impact on, or affect:	Potential positive and/or negative impacts	Recommendations for improvement/ mitigation (What could be put in place to decrease any potential negative impacts and increase potential positive impacts?)	Actions taken (and who by). (Refer to where the mitigation is included in the document, as appropriate. State what action will be taken?)
information leaflets, or service plans and design.	people who communicate using the Welsh language. Any patient-facing materials will be produced in Welsh and English, in line with the Welsh language standards, including easy read booklets.	language standards, including easy read booklets. These will be provided on the AWTTC website in accessible formats that can be printed.	
5.10 People according to their income related group.	We do not expect a potential negative, or unequal, impact on people based on their income-related group. In Wales, all prescription medicines are free-of-charge for patients; positive recommendations through this project will not affect people depending on their income-related group.	N/A	N/A

How will the project impact on, or affect:	Potential positive and/or negative impacts	Recommendations for improvement/ mitigation (What could be put in place to decrease any potential negative impacts and increase potential positive impacts?)	Actions taken (and who by). (Refer to where the mitigation is included in the document, as appropriate. State what action will be taken?)
5.11 People according to where they live.	We do not expect a potential negative, or unequal, impact on people based on where they live.	N/A	N/A
5.12 Consider others who face health inequalities, such as: • Looked after and accommodated children and young people • Carers: paid/unpaid, family members • People who are homeless or those who experience homelessness: people on the street; those staying temporarily with friends/family; those in hostels/B&Bs • People involved in the criminal justice system: offenders in prison or on probation, ex-offenders	We do not expect a potential negative, or unequal, impact on people who face health inequalities.	N/A	N/A

How will the project impact on, or affect:	Potential positive and/or negative impacts	Recommendations for improvement/ mitigation (What could be put in place to decrease any potential negative impacts and increase potential positive impacts?)	Actions taken (and who by). (Refer to where the mitigation is included in the document, as appropriate. State what action will be taken?)
• People with addictions and substance misuse problems • People who have poor literacy • People living in remote, rural and island locations			
5.13 Consider any other groups and risk factors relevant to this project.	N/A	N/A	N/A

6. HIA - How will the project impact on the health and wellbeing of people in Wales and help address inequalities in health?

Questions in this section relate to the impact on the overall health of individual people, and the impact on the population in Wales.

How will the project impact on, or affect:	Potential positive and/or negative impacts and any particular groups affected	Recommendations for improvement/ mitigation	Actions taken (and who by) <i>Refer to where the mitigation is included in the document, as appropriate.</i>
6.1 People being able to access the service offered.	We do not expect a potential negative, or unequal, impact on people's ability to access the service offered.	N/A	N/A
6.2 People being able to improve or maintain healthy lifestyles.	We do not expect a potential negative, or unequal, impact on people's ability to improve or maintain healthy lifestyles.	N/A	N/A
6.3 People in terms of their income and employment status.	We do not expect a potential negative, or unequal, impact on people in terms of their income and employment status.	N/A	N/A
6.4 People in terms of their use of the physical environment.	We do not expect a potential negative, or unequal, impact on people's use of the physical environment.	N/A	N/A
6.5 People in terms of social and community influences on their health.	We do not expect a potential negative, or unequal, impact on people in terms of social and community influences on their health.	N/A	N/A

How will the project impact on, or affect:	Potential positive and/or negative impacts and any particular groups affected	Recommendations for improvement/ mitigation	Actions taken (and who by) <i>Refer to where the mitigation is included in the document, as appropriate.</i>
6.6 People in terms of macro-economic, environmental and sustainability factors.	We do not expect a potential negative, or unequal, impact on people in terms of macroeconomic, environmental and sustainability factors.	N/A	N/A

7. Please fill in section 7.1 after completing the EqHIA, and fill in the action plan.

7.1 Please summarize the potential positive and/or negative impacts of the project.	
--	--

Action plan for mitigation or improvement and implementation

	Action	Lead(s)	Timescale	Actions taken
7.2 What are the key actions identified as a result of completing the EqHIA?	N/A	N/A	N/A	N/A
7.3 Is a more comprehensive Equalities Impact Assessment or Health Impact Assessment needed?	N/A	N/A	N/A	N/A
7.4 What are the next steps?	Consider for review in line with process, or if developments in evidence or changes in medicine usage arise.	AWTTC	July 2029 or earlier if necessary	N/A

	Action	Lead(s)	Timescale	Actions taken
7.5 Review of project and EqHIA	TBC			

AWTTC's EqHIA template is adapted from the Cardiff & Vale University Health Board EHIA template.